Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...
As shown in Figure 2 and 3, the pooled SMDs for alogliptin 12.5 mg treated vs controls, and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated ...
If you are already taking both alogliptin and metformin as separate tablets, Nesina Met can replace them in one tablet. Nesina Met is not for patients with type 1 diabetes mellitus or diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback